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Potential Use of MALDI-ToF Mass 
Spectrometry for Rapid Detection 
of Antifungal Resistance in the 
Human Pathogen Candida glabrata
Antonietta Vella1, Elena De Carolis1, Enrica Mello1, David S. Perlin2, Dominique Sanglard  3, 
Maurizio Sanguinetti  1 & Brunella Posteraro4
The echinocandins are relatively new antifungal drugs that represent, together with the older 
azoles, the recommended and/or preferred agents to treat candidaemia and other forms of invasive 
candidiasis in human patients. If “time is of the essence” to reduce the mortality for these infections, 
the administration of appropriate antifungal therapy could be accelerated by the timely reporting 
of laboratory test results. In this study, we attempted to validate a MALDI-ToF mass spectrometry-
based assay for the antifungal susceptibility testing (AFST) of the potentially multidrug-resistant 
pathogen Candida glabrata against anidulafungin and fluconazole. The practical applicability of the 
assay, reported here as MS-AFST, was assessed with a panel of clinical isolates that were selected 
to represent phenotypically and genotypically/molecularly susceptible or resistant strains. The data 
show the potential of our assay for rapid detection of antifungal resistance, although the MS-AFST 
assay performed at 3 h of the in vitro antifungal exposure failed to detect C. glabrata isolates with 
echinocandin resistance-associated FKS2 mutations. However, cell growth kinetics in the presence of 
anidulafungin revealed important cues about the in vitro fitness of C. glabrata isolates, which may lead 
to genotypic or phenotypic antifungal testing in clinical practice.
Infections caused by Candida species are particularly severe in immunocompromised patients, including 
HIV-infected, cancer and transplant patients1. The severity of these infections, especially candidaemia and 
deep-seated tissue candidiasis—both are forms of invasive candidiasis2, is associated with a concerted interplay 
between antifungal drug resistance, virulence and immune evasion traits3. Among non-albicans Candida species, 
C. glabrata is the second (after C. albicans) or third most common cause of fungal bloodstream infections in the 
US4, 5. Outside of the US or Northern Europe6, C. glabrata is less commonly isolated7. Nonetheless, C. glabrata 
manifests an intrinsically low susceptibility to azoles in vitro or tends to easily develop azole resistance during the 
course of antifungal therapy8, 9. Alarmingly, exposure of C. glabrata cells to an antifungal agent may lead to highly 
variable, “evolvable” genomes capable of quick development of resistance to multiple antifungal drug classes10, 
including triazoles (e.g. fluconazole) and echinocandins (e.g. anidulafungin).
Despite a very low echinocandin resistance in many centres/countries, a recent US study has shown that 
nearly one-third of the C. glabrata isolates resistant to at least one echinocandin were also resistant to flucona-
zole11. Interestingly, almost all of these isolates with either a resistant or intermediate echinocandin minimum 
inhibitory concentration (MIC) value had mutations in specific hot spot regions (e.g. HS1) of the FKS1 and FKS2 
genes11, which is the major mechanism of echinocandin resistance in Candida species12, 13. Such a mechanism 
is restricted and quite different from that of azoles14. Therefore, while direct molecular evaluation of the FKS 
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genotype can be ideal for echinocandin resistance15, this is not the same for azole resistance due to the complexity 
of underlying resistance mechanisms16.
The possibility of using matrix-assisted laser desorption ionization–time-of-flight mass spectrometry 
(MALDI-ToF MS) for determination of antimicrobial resistance has been recently investigated17 to expand the 
landscape of diagnostic applications of this powerful technology18. In the present study, a phenotypically oriented 
assay using MALDI-ToF MS was developed and validated to allow accurate detection of susceptibility/resistance 
to anidulafungin and fluconazole in C. glabrata isolates after antifungal exposure in vitro. The results suggest that 
the MALDI-ToF MS-based AFST assay, reported here as MS-AFST, has the potential to become a useful tool for 
rapid detection of antifungal resistance.
Results
Recently, we have proposed a simplified version of the MS-AFST assay19 that allowed successful discrimination 
between susceptible and resistant isolates of C. albicans only after 3 h of incubation of yeast cells in the presence 
of three concentrations of echinocandin (i.e. caspofungin): no drug (null concentration), intermediate (“break-
point” concentration) and maximum (maximal concentration)20.
In this study, C. glabrata was chosen as a model test organism for the validation of MS-AFST against anidu-
lafungin and fluconazole and the practical applicability of MS-AFST was demonstrated with a panel of 80 C. glabrata 
clinical isolates selected to represent phenotypically and genotypically/molecularly susceptible or resistant strains 
(Supplementary Table 1).
Optimizing MALDI-ToF MS analysis. First, we set up experiments with 10 C. glabrata isolates represent-
ative of wild-type (WT; without acquired mutational or other resistance mechanisms) or non-wild-type (NWT; 
with acquired mutational or other resistance mechanisms) phenotypes (Supplementary Table 1). Following expo-
sure for 3 h to anidulafungin or fluconazole, mass spectra obtained from these isolates were subjected to compos-
ite correlation index (CCI) analysis—a CCI value near 1.0 indicates relatedness between the spectral sets, and 0 
indicates no match—in order to identify, respectively, the “breakpoint” concentration spectrum to be compared 
with the spectra at two extreme drug concentrations (null or maximal). As a result, 0.06 µg/mL for anidulafungin 
and 16 µg/mL for fluconazole were identified as the respective concentrations at which the CCI values obtained by 
matching the “breakpoint” spectrum with the spectrum at maximal drug concentration (maximum CCIs) were, 
respectively, higher (for all the 5 WT isolates) or lower (for all the 5 NWT isolates) than the CCI values obtained 
when the “breakpoint” spectrum was matched with the spectrum at null drug concentration (null CCIs).
The reproducibility of MS-AFST assays was assessed for the 10 reference isolates tested on two different days. 
In all the analyses, CCI values from the isolates’ biological replicates differ uniformly (p < 0.05, unpaired t-test). 
Although absolute CCI values (maximum and null) varied among the two replicates, the CCI ratios expressed 
as CCImax/CCInull were always higher than 1 for the WT isolates and lower than 1 for the NWT isolates (data not 
shown). The classification results by the MS-AFST assays were consistent with the isolates’ MIC values and the 
respective susceptibility categories—as established by the Clinical and Laboratory Standards Institute (CLSI)—
shown in Supplementary Table 1.
Using MS-AFST assay for discrimination between anidulafungin-resistant and anidulafungin- 
susceptible isolates. Table 1 shows the classification results for all the 80 C. glabrata isolates included in the 
study, which were tested with the MS-AFST assay using the three established concentrations (0, 0.06 and 32 µg/
mL) of anidulafungin.
Genotype (no. of isolates)
MIC range, 
expressed as μg/mL
Classification by MS-AFST 
assay (no. of isolates)
WT (58) ≤0.016–1 Susceptible (57), resistant (1)
FKS1
F625S (2) 1–2 Resistant (2)
S629P (2) 2–4 Resistant (2)
D632E (2) 1 Resistant (2)
FKS2
F659V (2) 1 Susceptible (2)
S663P (8) 0.25–4 Resistant (3), susceptible (5)
R665G (1) 0.25 Susceptible (1)
R665S (1) 0.12 Susceptible (1)
D666E (1) 0.25 Susceptible (1)
D666G (1) 2 Resistant (1)
P667T (2) 0.25–1 Susceptible (2)
Table 1. MS-AFST assay results for the 80 C. glabrata isolates tested against anidulafungin. Classification of the 
isolates as susceptible or resistant to the antifungal drug is shown according to the FKS HS1 genotypes and MIC 
values.
www.nature.com/scientificreports/
3SCIentIFIC REPORTS | 7: 9099  | DOI:10.1038/s41598-017-09329-4
Overall, 86.2% (69/80) of the isolates were classified as susceptible and 13.8% (11/80) of the isolates were 
classified as resistant to anidulafungin. According to FKS1/FKS2 HS1 genotypes, 57 (98.3%) of 58 isolates with 
WT sequences were classified as susceptible, 6 (100%) of 6 isolates with mutated FKS1 sequences were classified 
as resistant, and 4 (25.0%) of 16 isolates with mutated FKS2 sequences were classified as resistant. According to 
CLSI MIC breakpoints, 58 (100%) of 58 isolates in the susceptible category were classified as susceptible, and 11 
(50.0%) of 22 isolates in the nonsusceptible (intermediate or resistant) category were classified as resistant. As 
shown in Fig. 1a, among 11 isolates with a CCImax/CCInull ratio <1 (i.e. MS-AFST assay-classified as resistant), 4 
isolates had MICs of 1 µg/mL, 4 isolates had MICs of 2 µg/mL, and 3 isolates had MICs of 4 µg/mL; among 69 iso-
lates with a CCImax/CCInull ratio >1 (i.e. MS-AFST assay-classified as susceptible), 58 isolates had MICs ranging 
from 0.016 to 0.125 µg/mL, 4 isolates had MICs of 0.25 µg/mL, and 7 isolates had MICs ranging from 1 to 2 µg/mL.
Figure 1. Distribution of results from the MS-AFST assay for the 80 C. glabrata isolates according to the MIC 
values as determined by the reference CLSI method. The isolates were tested against the antifungal drugs 
anidulafungin (a) and fluconazole (b). For each isolate, the MIC value (x-axis) was plotted against the CCImax/
CCInull ratio (y-axis). The latter was calculated as the maximum CCI value (i.e. the value obtained by matching 
the breakpoint spectrum with the spectrum at maximal drug concentration) divided by the null CCI value (i.e. 
the value obtained by matching the breakpoint spectrum with the spectrum at null drug concentration). Isolates 
were called susceptible if the CCImax/CCInull ratio was higher than 1, whereas isolates were called resistant if the 
CCImax/CCInull ratio was lower than 1. In the (a) and (b) graphs, solid lines indicate the MIC breakpoints for 
resistance to anidulafungin (≥0.5 µg/mL) and fluconazole (≥64 µg/mL), whereas the dotted line indicates the 
MIC breakpoint for the intermediate (0.25 µg/mL) susceptibility to anidulafungin. In (a) the red circle denotes 
isolates with MICs in the intermediate (n = 4) or resistance (n = 7) range to anidulafungin, whereas in (b) red 
arrows indicate single isolates with MICs in the dose-dependently susceptibility (n = 1) or resistance (n = 2) 
range to fluconazole; all the 11 isolates (8 for anidulafungin and 3 for both anidulafungin and fluconazole) had 
classification results by the MS-AFST assay that did not agree with the categorization results obtained by the 
reference CLSI method.
www.nature.com/scientificreports/
4SCIentIFIC REPORTS | 7: 9099  | DOI:10.1038/s41598-017-09329-4
Using MS-AFST assay for discrimination between fluconazole-resistant and fluconazole- 
susceptible isolates. Table 2 shows the classification results for the aforementioned 80 C. glabrata isolates 
that were tested with the MS-AFST assay using the three established concentrations (0, 16 and 256 µg/mL) of 
fluconazole. 
Overall, 52.5% (42/80) of the isolates were classified as susceptible and 47.5% (38/80) of the isolates were 
classified as resistant to fluconazole. According to the underlying resistance mechanism, 40 (97.6%) of 41 isolates 
with a basal level of CDR1/CDR2 expression were classified as susceptible, whereas 37 (94.9%) of 39 isolates 
with an increased level of CDR1/CDR2 expression were classified as resistant. According to CLSI MIC break-
points, 40 (97.6%) of 41 isolates in the susceptible dose-dependent category were classified as susceptible, and 37 
(94.9%) of 39 isolates in the resistant category were classified as resistant. As shown in Fig. 1b, among 38 isolates 
with a CCImax/CCInull ratio <1 (MS-AFST assay-classified as resistant), 37 isolates had MICs ranging from 64 
to 128 µg/mL, and 1 isolate had a MIC of 8 µg/mL; among 42 isolates with a CCImax/CCInull ratio >1 (MS-AFST 
assay-classified as susceptible), 40 isolates had MICs ranging from 2 to 32 µg/mL, and 2 isolates had MICs ranging 
from 64 to 128 µg/mL.
Resolving the misclassification errors obtained with MS-AFST assay. The performances of both 
MS-AFST assay and CLSI method for the 80 C. glabrata isolates were compared to the antifungal-resistance 
molecular analysis results (Supplementary Table 2). As many as 11 very major errors (i.e. if a resistant isolate was 
misclassified as susceptible) occurred when testing anidulafungin, whereas only 2 very major errors did when 
testing fluconazole, with the MS-AFST assay. Interestingly, 3 of the 11 errors concerned the isolates DSP220, 
DSP221 and DSP259, which were misclassified as resistant (1 isolate) or susceptible (2 isolates) against flucona-
zole. The major error (i.e. if a susceptible isolate was misclassified as resistant) with anidulafungin for the isolate 
DSP182 was not further evaluated because it was also considered resistant by the CLSI method.
Therefore, we performed MS-AFST-assays with the 11 isolates incubated in the presence of antifungal drugs 
for times higher than 3 h (i.e. 6-, 9- and 12-h incubations; see Supplementary Table 3). Two errors (only for anid-
ulafungin) regarding isolates DSP282 and DSP314 were still unresolved. However, when MS-AFST assays were 
performed at 15 h of incubation with both the antifungal drugs, we found 100% essential agreement between 
minimal profile change concentration (MPCC) values and MICs for all the 11 isolates (Supplementary Table 3).
Determining in vitro growth kinetics to reveal differences between FKS1 and FKS2 mutant iso-
lates. To investigate whether the different capability of the MS-AFST assay in discriminating among C. gla-
brata isolates with mutated FKS1 or FKS2 genotypes might be reflected by a differentially defective cell growth, 
in vitro growth of 24C. glabrata isolates (2 FKS1/FKS2-WT; 6 FKS1-NWT and 16 FKS2-NWT) was recorded in 
the presence of anidulafungin.
The growth curves of C. glabrata isolates DSP2 (FKS1/FKS2-WT), DSP224 (FKS1-S629P), DSP34 
(FKS2-P667T) and DSP186 (FKS2-S663P) are shown, as representative examples, in Supplementary Fig. 1 and 
Fig. 2. Overall, growth curves obtained from the isolates in the presence or absence of anidulafungin were super-
imposable for both WT and FKS1-NWT isolates but not for FKS2-NWT isolates. For these last isolates, two 
growth profiles could be noticed, of which one very similar to that the FKS1-NWT isolates and another quite dif-
ferent from that of WT or FKS1-NWT isolates—thus isolates corresponding to the two profiles were designated 
as FKS2-NWTfast and FKS2-NWTslow, respectively.
Next, the cell doubling times of anidulafungin-exposed and unexposed isolates’ cells were compared among 
groups of FKS1-NWT or FKS2-NWT isolates (Fig. 2). Overall, no statistically significant differences in the mean 
doubling-time values were noticed (p > 0.05, for all comparisons; paired t-test) (Fig. 2a), whereas the mean 
lag-time values differed considerably (Fig. 2b). Interestingly, among the FKS2-NWT isolates, the FKS2-NWTslow 
subgroup displayed mean lag-time values that were higher than those of the FKS2-NWTfast subgroup (9.9 ± 4.2 h 
vs 3.1 ± 1.5 h, p < 0.05; unpaired t-test). These times were sufficiently prolonged to allow the FKS2-NWTfast iso-
lates to exhibit a profile of expressed proteins enabling them to be correctly classified by the MS-AFST assay.
Discussion
In the present study, we were able to detect changes in the protein spectrum of C. glabrata in the presence or 
absence of anidulafungin or fluconazole that correlate with drug susceptibility changes. Overall, applying the 
3 h MS-AFST assay on a panel of 80 C. glabrata isolates, we detected 85.0% (68/80) and 96.2% (77/80) of isolates 
with results of classification for anidulafungin and fluconazole, respectively, that were in full agreement with 
those obtained by antifungal-resistance mechanisms (FKS1/FKS2 genotype or (Cg)CDR1/CDR2 overexpression). 
Duplicate testing of each isolate on different runs against anidulafungin or fluconazole was performed to eval-
uate the robustness of the dual MS-AFST assay. Reproducibility rates of 98.7% and 97.5% were obtained when 
testing anidulafungin and fluconazole, respectively, with only 3 inconsistencies (1 for anidulafungin and 2 for 
CDR1/CDR2 expression 
(no. of isolates)
MIC range, 
expressed as μg/mL
Classification by MS-AFST 
assay (no. of isolates)
Basal (41) 2–32 Susceptible (40), resistant (1)
Increase (39) 64–>64 Resistant (37), susceptible (2)
Table 2. MS-AFST assay results for the 80 C. glabrata isolates tested against fluconazole. Classification of the 
isolates as susceptible or resistant to the antifungal drug is shown according to the CDR expression levels and 
MIC values.
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fluconazole)—subsequently arbitrated by a third run before including them in the final analysis (see Materials and 
Methods). These data allow us to be confident about the accuracy of MS-AFST assays, although our results differ 
in some respects from those of previous investigators. In a recent evaluation of our assay by Saracli et al.21—the 
authors employed a modification of the assay originally developed by our laboratory19—the reproducibility of 
the MALDI-ToF MS-based assay for discrimination of susceptible and resistant isolates of Candida species to 
triazoles varied between 54.3% and 82.9%. However, consistent with our study, the reproducibility was higher for 
C. glabrata isolates (77.1% for fluconazole) than for isolates from other Candida species21.
When the MS-AFST assay results for anidulafungin were analysed according to the FKS1 or FKS2 geno-
type, we found 100% and 25.0% agreement for isolates (6/6) with a mutated FKS1 gene and for isolates (4/16) 
with a mutated FKS2 gene, respectively. Accordingly, 15.0% of incorrect classification results for anidulafungin 
were assigned to FKS2 HS1 mutations, and these results were distributed among all 7 different mutated FKS2 
genotypes included in this study. In particular, we noticed that the isolates harbouring the mutations F659V 
(2 isolates), R665G (1 isolate), R665S (1 isolate), D666E (1 isolate) and P667T (2 isolates) were classified as 
anidulafungin-susceptible, whereas 1 isolate harbouring the D666G mutation and 3 of 8 isolates harbouring the 
S663P mutation were all classified as anidulafungin-resistant by the MS-AFST assay. However, the above overall 
rates of 85.0% and 96.2% increased to 97.5% and 100% for anidulafungin and fluconazole, respectively, when the 
11 of 79 isolates—(excluding the isolate DSP182)—with incorrect classifications (8 to anidulafungin and 3 to both 
anidulafungin and fluconazole) were tested by prolonged antifungal drug exposures (up to 6–12 h). Two of 11 iso-
lates, DSP282 (FKS2-R665G) and DSP314 (FKS2-P667T), were still not correctly classified by the MS-AFST assay, 
although their MPCC values—determined at a 15-h anidulafungin exposure—were identical to the CLSI MIC 
values (0.25 µg/mL). Together, this indicates that incubation times ranging between 12 and 15 h allow to correctly 
Figure 2. Cell growth parameters determined by an algorithm-based automatic calculation for C. glabrata 
isolates exposed to anidulafungin. A total of 24 isolates, 2 with WT FKS genes, 6 with NWT FKS1 genes and 
16 with NWT FKS2 genes were compared. For each group, growth parameters were evaluated in the isolates 
exposed to 0.06-µg/mL anidulafungin (AND) in comparison to the same isolates that were not exposed to the 
antifungal drug. Two subgroups of FKS2-NWTfast and FKS2-NWTslow isolates, i.e. identified within the FKS2-
NWT isolates based on marked differences in their cell growth profiles, were also compared. The cell doubling 
times (in h) are measured at the maximal growth rate. The lag times (in h) represent the mean ± SD of three 
independent growth curves of cells exposed at the same time.
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identify these isolates with our assay. Unfortunately, the 3 h AFST format assay in the presence of echinocandin 
failed to accurately detect C. glabrata isolates with FKS2 mutations. Thus, the goal/benefit of providing reliable 
echinocandin resistance/susceptibility information on the same day was only partially reached with this specific 
antifungal agent in C. glabrata.
To attempt to elucidate the above deficiencies of the MS-AFST assay, 22 isolates with FKS mutations and 2 
FKS-WT isolates were analysed for quantitative changes in cell growth under exposure to anidulafungin. We 
used a micro-culture growth curve assay in the presence of 0.06 µg/mL of anidulafungin (the “breakpoint” con-
centration used in the MS-AFST assay). This allowed us to profile growth with the lag times and subsequent 
growth rates. We found that the lag times in response to anidulafungin differed between FKS1-NWT isolates and 
FKS2-NWT isolates, and these differences were particularly marked between two subgroups of FKS2-NWT iso-
lates. Indeed, among the FKS2-NWTslow isolates, 1 isolate (DSP235; MIC, 0.125 µg/mL) had a growth profile sim-
ilar to that of the WT isolates, and other 2 isolates (the aforementioned DSP282 and DSP314; MIC, 0.25 µg/mL) 
did not grow under the experimental conditions—likely due to problems intrinsic to the micro-culturing22. 
Excluding the 3 isolates, the 9 FKS2-NWTslow isolates were greatly slowed in comparison with the 4 FKS2-NWTfast 
isolates (DSP30, DSP32, DSP186 and DSP249), consistent with the observation that the latter isolates did reach 
in short times (i.e. ≤3 h) a cell protein expression level enough to be correctly classified by the MS-AFST assay. 
Notably, the mean lag time of FKS2-NWTfast isolates was very similar to that of the FKS1-NWT isolates (1.28 
vs 1.84, p = 0.476). Also, we were not surprised to find that all the 9 FKS2-NWTslow isolates gave a correct clas-
sification result by the MS-AFST assay only after prolonged times (i.e. >3 h) of anidulafungin exposure. Since 
differences in cell growth between the two subgroups did not seem to be affected by the type of FKS2 mutation, 
a strain-specific genetic background, overwhelming the effect of the mutated FKS2 genotype, may explain the 
initially incorrect classification results by the MS-AFST assay.
In conclusion, our study is the first to evaluate the use of the MS-AFST assay on C. glabrata isolates with anid-
ulafungin and fluconazole. The method in its quick version (3 h format) was highly specific for identifying isolates 
with altered FKS1 gene sequences and/or CDR1/CDR2 gene expression levels. Although no controls with other 
Candida species were included, our previous study with C. albicans and caspofungin suggests that FKS1 can be 
considered an easily attainable target for the rapid assessment of echinocandin resistance. As above mentioned, 
we have shown that MS-AFST correctly classified 100% (51/51) and 90.9% (10/11) of WT and FKS1 mutant iso-
lates of C. albicans as caspofungin-susceptible and caspofungin-resistant, respectively20. Future studies are needed 
to validate our findings. In the meanwhile, as clinical experience suggests to use alternative antifungal classes for 
treating patients with previous echinocandin exposure, our MALDI-ToF MS assay, as shown in Fig. 3, could be 
used as a valuable tool for rapid detection of C. glabrata isolates as fluconazole-resistant, which could alert about 
the potential presence of anidulafungin resistance in these isolates.
Figure 3. Flow chart diagram illustrating the potential use of the dual MS-AFST in clinical practice. A scenario 
of prior echinocandin exposure is shown, where MS-AFST results for a C. glabrata clinical isolate as susceptible 
or resistant to anidulafungin (AND) and/or fluconazole (FLC) may be useful to drive the appropriate 
administration of antifungal therapy. For AND, valid MS-AFST results can be available after 3 h or, in cases of 
isolates with FKS2 HS1 mutations, 6–12 h of antifungal exposure in vitro.
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Materials and Methods
Yeast organisms and growth conditions. A total of 80 C. glabrata isolates was included in the study, 
that comprised WT and NWT isolates—the latter with FKS1/FKS2 mutations and/or CDR1/CDR2 overexpres-
sion—mostly recovered from clinical specimens. The isolates were retrieved from strain collections in the Perlin 
(DSP isolates), Sanglard (DSY or SFY isolates) or Sanguinetti (UCSC isolates) laboratories at the Public Health 
Research Institute, the University Hospital of Lausanne and the Università Cattolica del Sacro Cuore, Fondazione 
Policlinico Universitario Agostino Gemelli, respectively. As detailed in Supplementary Table 1, the set of isolates 
consisted of anidulafungin-susceptible, anidulafungin-intermediate, anidulafungin-resistant, fluconazole-suscep-
tible dose-dependent and fluconazole-resistant isolates, and 11 of these isolates were resistant (nonsusceptible) to 
both anidulafungin and fluconazole. All the isolates were reanalysed for AFST before to be utilized in this study 
(see below). The mutations in HS1 of FKS1 and FKS2 genes were detected by DNA sequencing as reported else-
where23, whereas the overexpression of (Cg)CDR1 and (Cg)CDR2 genes was assessed by quantitative real-time 
PCR analysis using the primers and thermal conditions previously described24, 25. Prior to testing, isolates were 
grown on YPD (yeast extract/peptone/dextrose) agar plates, unless otherwise specified.
AFST by the reference method. Susceptibility testing of C. glabrata isolates to anidulafungin and flucona-
zole was performed according to the CLSI M27-A3 guidelines26, using microdilution-broth trays custom pre-
pared with pure antifungal substances (anidulafungin provided by Pfizer, New York, NY; fluconazole provided by 
Sigma-Aldrich, St. Louis, MO) in the UCSC laboratory. Results were read after 24-h incubation of trays to deter-
mine, for each isolate, the MIC to antifungal drug as the lowest concentration of drug that caused a 50% growth 
reduction compared to the drug-free control well. The MICs to both the antifungals were interpreted using the 2012 
CLSI M27-S4 breakpoints27. For anidulafungin, isolates were categorized as susceptible (MIC, ≤0.125 µg/mL), 
intermediate (MIC, 0.25 µg/mL) or resistant (≥0.5 µg/mL); however, for comparison purposes, isolates with MICs 
in the intermediate or resistance range to anidulafungin were conceptually placed into a nonsusceptible category, 
and thus considered as resistant. For fluconazole, isolates with an MIC of ≤32 µg/mL were categorized as sus-
ceptible dose-dependent, whereas isolates with an MIC of ≥64 µg/mL were categorized resistant; however, for 
comparison purposes, isolates with MICs in the susceptible dose-dependent range was considered as susceptible. 
This was in keeping with acceptance criteria published elsewhere21, 28.
MALDI-ToF MS assays, data analysis, and reproducibility assessment. Samples for MALDI-ToF 
MS were prepared in duplicate by following analytical methods previously developed by us19, 20. In the first 
study phase, yeast cells (1 × 107 CFU/mL) were exposed, in RPMI, to six different antifungal-drug concentra-
tions (0.03 µg/mL to 16 µg/mL for anidulafungin, and 4 µg/mL to 128 µg/mL for fluconazole), and two additional 
antifungal-drug concentrations such as a maximal concentration (32 µg/mL for anidulafungin and 256 µg/mL 
for fluconazole) and a null concentration (0 µg/mL). After establishing the breakpoint antifungal-drug 
concentration20, in the second study phase, yeast cells (1 × 107 CFU/mL) were exposed to the following 
antifungal-drug concentrations: 32 µg/mL, 0.06 µg/mL and 0 µg/mL for anidulafungin, and 256 µg/mL, 16 µg/mL 
and 0 µg/mL for fluconazole. After 3 h at 37 °C under agitation, cells were harvested by centrifugation, washed 
twice with deionized water, and re-suspended in 10% formic acid. One microliter of the lysate from each sample 
was used for the analysis which was performed, in duplicate, with the Bruker Daltonics MALDI Biotyper 3.1 
software on a Microflex LT mass spectrometer (Bruker Daltonics, Bremen, Germany). The protein mass spectra 
were acquired in the positive linear mode and analysed in the mass range of 4,000 to 9,000 m/z, starting from 
measuring a larger mass range (2,000 to 20,000 m/z), by using 240 laser shots (40 laser shots at 6 different spot 
positions) for each spectrum and by instrument parameters previously established (ion source 1, at 20 kV; ion 
source 2, 16.7 kV; and lens, 8.5 kV)20. Before each run, the instrument was calibrated with Bacterial Test Standard 
(Bruker Daltonics).
The MALDI Biotyper 3.1 software was used for comparing the spectra with one another at the antifungal 
drug concentrations tested, as above mentioned, by means of the automatic visualization of raw spectra in a CCI 
matrix view, where CCI values around 1 represent high similarity of spectra and CCI values near 0 indicate clear 
diversity of the spectra. Based on previous studies from our group19, 20, the maximum CCI (CCImax) value and the 
null CCI (CCInull) value were computed, respectively, by matching each breakpoint spectrum with the spectrum 
at the maximal concentration of or with the spectrum at null concentration of antifungal drug. In addition, CCI 
ratios were obtained by dividing the CCImax by the CCInull and expressed as CCImax/CCInull, and were then used as 
a measure to evaluate the spectral variation within the single isolate.
As a first step of evaluation, the reproducibility of the analytical method was assessed with the spectra 
obtained from two biological replicates (i.e. prepared from cultivations of the same isolate on two different days) 
for representative isolates, which were selected from the isolate set of the study as specified above. In a next step, 
samples from all the study isolates were blind-coded, extracted, and subjected to MALDI-ToF MS analysis in two 
different days, and the results of the analyses were compared. The MS-AFST MS assay was considered reproduci-
ble when the same classification assessment was obtained after repeat testing regardless of its agreement with the 
categorical result obtained with the method used as a comparator (see below). In cases of inconsistency between 
the replicates, the analysis was repeated once again—this occurred in 1 case for anidulafungin and 2 cases for flu-
conazole, accounting for reproducibility rates of 98.7% and 97.5%, respectively. In these cases, concordant results 
of two of three runs were accepted for the final analysis. In addition, MALDI-ToF MS assays were also performed 
according to the original version of our AFST method to determine the MPCC to anidulafungin for those isolates 
that had discordant results with those of the comparator method (see below).
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Analysis of test results. Results from the MS-AFST assay were interpreted according to pre-definite 
criteria, by which a C. glabrata isolate was classified as susceptible or resistant to the drug if the CCI value 
derived from the correlation of spectra at the breakpoint and the maximal drug concentrations was, respec-
tively, higher or lower than the CCI value derived from the correlation of spectra at the breakpoint and null drug 
concentrations20. The FKS1/FKS2 genotype (for anidulafungin) or the CDR overexpression (for fluconazole) was 
used as a gold standard to calculate the percentage categorical agreement as a means of evaluating the perfor-
mance of the MS-AFST assay. Very major errors were recorded when NWT isolates were classified as suscep-
tible by the MS-AFST assay, and major errors were recorded when WT isolates were classified as resistant by 
the MS-AFST assay. Minor errors were not recorded because an intermediate category was not available by the 
MS-AFST assay. The performance of the CLSI method was evaluated in parallel as described for the MS-AFST 
assay. In addition, categorical agreement as well as very major or major errors of the MS-AFST assay were evalu-
ated by comparison with the results from the CLSI method.
In vitro cell growth analysis. To quantitate in vitro growth changes in C. glabrata isolates following expo-
sure to anidulafungin, a methodology based on the micro-cultivation of yeast cells in liquid media was used22. 
By this way, pre-prepared growing media into microplates are inoculated with very small (100 µL) aliquots of 
pre-cultures (starting from single colonies and incubated overnight), and cell population is automatically mon-
itored at regular time intervals for 48 h. In this study, C. glabrata isolates were grown exponentially to a density 
of 0.7 × 107 to 107 cells/mL (optical density [OD] at 660 nm  ~0.5–0.7) in YPD medium at 30 °C under constant 
agitation. Then, cells were harvested by centrifugation, washed with sterile water and re-suspended to a density of 
0.8 × 107 cells/mL. For each isolate, triplicates of wells containing 95 µL of YPD medium with 0.06-µg/mL anid-
ulafungin (treated samples) or without anidulafungin (control samples) were each inoculated with 5 µL (4 × 104 
cells) of the washed cell suspension in a 96-well microplate. Three wells for the blank, with no cells in them, were 
included in the microplate. The cell population was monitored with a microplate scanning spectrophotometer 
(BioTek Absorbance Microplate Reader; Winooski, VT) at 30 °C. The OD of cell population was recorded every 
15 min during 48 h at the wavelength of 630 nm, by using the Gen5 Reader Control Software of the BioTek instru-
ment. The data were exported to Excel (Microsoft) and the raw OD curves were plotted to derive growth curves. 
For data quantification, we followed a well-established algorithm22 that allows the automatic calculation of growth 
parameters. In this algorithm, cell growth is represented by the logarithmic curve, Ln (OD/ODi), where ODi is 
the initial OD; the maximal growth rate (μm) corresponds to the maximal slope of the Ln curve, and the cell dou-
bling time at μm is defined by ln(2)/μm; ultimately, the lag time (λ) corresponds to the intersection of the maximal 
slope of the Ln curve with the x-axis.
Guidelines and regulations. No human subjects or human tissue were used in this study, therefore no 
human consent was required.
Statistical analysis. The data were expressed as the mean ± the standard deviation (SD). Statistical signifi-
cance was assessed using paired or unpaired t-tests. A p value of less than 0.05 was considered significant.
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